[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wen-hong Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100513432","predictive-value-of-hbv-pgrna-on-long-term-outcomes-in-hepatitis-b-patients-treated-with-antiviral-therapy-100513432",false,"NCT05965388","Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy","Inclusion Criteria:\n\n* CHB defined as positive hepatitis B surface antigen at least 6 months, or HBV-related histological changes within 1 year if HBsAg positive less than 6 months;\n* Age between 18-80 years, gender is not limited；\n* Patients with chronic hepatitis B who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon \\[IFN\\] monotherapy, a potent nucleos(t)ide analogue \\[NA\\] monotherapy, two different potent NAs combination therapy, or NA plus IFN combination therapy;\n* Patient who reads and signs informed consent.\n\nExclusion Criteria:\n\n* Patients with malignancies other than hepatocellular carcinoma.","ALL","18 Years","80 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B.\n\nParticipants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.",[24,25],"HBV","HCC","NOT_YET_RECRUITING","2023-07-20",{"date":29,"type":30},"2023-07-28","ACTUAL",{"date":32,"type":20},"2023-12-01",{"date":34,"type":20},"2029-02-01",{"name":36,"class":37},"Wen-hong Zhang","OTHER",10,""]